On January 11, 2021 Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics, reported a strategic collaboration with Almac Diagnostic Services to enhance opportunities for clinical trial development and companion diagnostic (CDx) projects (Press release, Almac, JAN 11, 2021, View Source [SID1234575423]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
PGDx and Almac Diagnostic Services will focus on providing access to tumor profiling assays for both tissue and plasma samples, specifically, PGDx elio tissue complete and PGDx elio plasma resolve. This collaboration will combine Almac’s world-class genomics services and expertise in development and delivery of molecular diagnostics with PGDx’s leadership in cancer genomics to accelerate solutions that will deliver precision medicine to more patients.
"We are proud to enter into this strategic collaboration with Almac. Their longstanding reputation for providing high quality lab services to patients worldwide, along with their proven track record of implementing new technologies make this partnership ideal," said Megan Bailey, CEO, PGDx. "As we continue our quest to empower the fight against cancer, collaborating with Almac will allow us to deliver precision medicine solutions to a broader population and advance innovations in next-generation sequencing technology."
Michael Sloan, Global Vice President of Commercial Operations, Almac Diagnostic Services said: "This collaboration with PGDx will enable Almac to provide our Pharmaceutical and Biotech partners with tissue and liquid biopsy options to support their translational research, clinical trials and CDx development requirements. The assay panels PGDx have developed will allow our clients to access world-class next generation sequencing science and bioinformatics solutions."